secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pasithea Therapeutics Corp. (KTTA)
CIK:        0001841330
Form:       8-K
Filed at:   2023-12-19T23:59:59+00:00
Accession:  0001213900-23-097013
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pasithea shareholders approve 2023 equity plan and reverse split authorization
------------------------------------------------------------------------------

- Stockholders approved Pasithea 2023 Stock Incentive Plan: 2.5M shares reserved plus rollover of unused 2021 plan shares.
- Reverse stock split authorized (1:2 to 1:20) at Board discretion within one year; corresponding reduction in authorized shares allowed.
- All five director nominees elected: Dr. Tiago Reis Marques, Prof. Lawrence Steinman, Simon Dumesnil, Dr. Emer Leahy, Alfred Novak.
- Marcum LLP ratified as independent auditor for FY 2023; annual meeting partially adjourned to Dec. 28 for additional governance proposals.
- Proxies remain open only for adjourned proposals (charter amendment, classified board, written consent restrictions).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841330/000121390023097013/0001213900-23-097013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841330/000121390023097013/ea190360-8k_pasithea.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-097013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer